Literature DB >> 29150495

Small dense HDLs display potent vasorelaxing activity, reflecting their elevated content of sphingosine-1-phosphate.

Laurence Perségol1, Maryam Darabi2, Carolane Dauteuille2, Marie Lhomme3, Sandrine Chantepie2, Kerry-Anne Rye4, Patrice Therond5, M John Chapman2, Robert Salvayre6, Anne Nègre-Salvayre6, Philippe Lesnik2, Serge Monier1, Anatol Kontush7.   

Abstract

The functional heterogeneity of HDL is attributed to its diverse bioactive components. We evaluated whether the vasodilatory effects of HDL differed across HDL subpopulations, reflecting their distinct molecular composition. The capacity of five major HDL subfractions to counteract the inhibitory effects of oxidized LDL on acetylcholine-induced vasodilation was tested in a rabbit aortic rings model. NO production, an essential pathway in endothelium-dependent vasorelaxation, was studied in simian vacuolating virus 40-transformed murine endothelial cells (SVECs). Small dense HDL3 subfractions displayed potent vasorelaxing activity (up to +31% vs. baseline, P < 0.05); in contrast, large light HDL2 did not induce aortic-ring relaxation when compared on a total protein basis. HDL3 particles were enriched with sphingosine-1-phosphate (S1P) (up to 3-fold vs. HDL2), with the highest content in HDL3b and -3c that concomitantly revealed the strongest vasorelaxing properties. NO generation was enhanced by HDL3c in SVECs (1.5-fold, P < 0.01), a phenomenon that was blocked by the S1P receptor antagonist, VPC 23019. S1P-enriched reconstituted HDL (rHDL) was a 1.8-fold (P < 0.01) more potent vasorelaxant than control rHDL in aortic rings. Small dense HDL3 particles displayed potent protective effects against oxidative stress-associated endothelium dysfunction, potentially reflecting their elevated content of S1P that might facilitate interaction with S1P receptors and ensuing NO generation.
Copyright © 2018 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  atherosclerosis; endothelium; high density lipoprotein; nitric oxide; oxidized low density lipoprotein; vasodilation

Mesh:

Substances:

Year:  2017        PMID: 29150495      PMCID: PMC5748494          DOI: 10.1194/jlr.M076927

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  61 in total

1.  Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome.

Authors:  Monica Gomaraschi; Alice Ossoli; Elda Favari; Maria Pia Adorni; Gianfranco Sinagra; Luigi Cattin; Fabrizio Veglia; Franco Bernini; Guido Franceschini; Laura Calabresi
Journal:  Cardiovasc Res       Date:  2013-06-28       Impact factor: 10.787

2.  Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities.

Authors:  Laurent Camont; Marie Lhomme; Fabiana Rached; Wilfried Le Goff; Anne Nègre-Salvayre; Robert Salvayre; Catherine Calzada; Michel Lagarde; M John Chapman; Anatol Kontush
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-10-03       Impact factor: 8.311

3.  Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes : impact of the degree of triglyceridemia.

Authors:  M Guérin; W Le Goff ; T S Lassel; A Van Tol ; G Steiner; M J Chapman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-02       Impact factor: 8.311

Review 4.  The role of serum amyloid A and sphingosine-1-phosphate on high-density lipoprotein functionality.

Authors:  Nicole Prüfer; Burkhard Kleuser; Markus van der Giet
Journal:  Biol Chem       Date:  2015-06       Impact factor: 3.915

5.  No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.

Authors:  Laurence Perségol; Laurence Duvillard; Serge Monier; Marie-Claude Brindisi; Benjamin Bouillet; Jean-Michel Petit; Bruno Vergès
Journal:  J Clin Endocrinol Metab       Date:  2014-08-19       Impact factor: 5.958

6.  Inability of HDL from abdominally obese subjects to counteract the inhibitory effect of oxidized LDL on vasorelaxation.

Authors:  Laurence Perségol; Bruno Vergès; Philippe Gambert; Laurence Duvillard
Journal:  J Lipid Res       Date:  2007-02-28       Impact factor: 5.922

7.  ATP-binding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase.

Authors:  Naoki Terasaka; Marit Westerterp; Joris Koetsveld; Carlos Fernández-Hernando; Laurent Yvan-Charvet; Nan Wang; William C Sessa; Alan R Tall
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-08-26       Impact factor: 8.311

8.  Psoriasis alters HDL composition and cholesterol efflux capacity.

Authors:  Michael Holzer; Peter Wolf; Sanja Curcic; Ruth Birner-Gruenberger; Wolfgang Weger; Martin Inzinger; Dalia El-Gamal; Christian Wadsack; Akos Heinemann; Gunther Marsche
Journal:  J Lipid Res       Date:  2012-05-30       Impact factor: 5.922

9.  Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity.

Authors:  Boris Hansel; Philippe Giral; Estelle Nobecourt; Sandrine Chantepie; Eric Bruckert; M John Chapman; Anatol Kontush
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

10.  Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling.

Authors:  Meliana Riwanto; Lucia Rohrer; Bernd Roschitzki; Christian Besler; Pavani Mocharla; Maja Mueller; Damir Perisa; Kathrin Heinrich; Lukas Altwegg; Arnold von Eckardstein; Thomas F Lüscher; Ulf Landmesser
Journal:  Circulation       Date:  2013-01-24       Impact factor: 29.690

View more
  8 in total

1.  Evacetrapib reduces preβ-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes.

Authors:  Yunqin Chen; Jibin Dong; Xiaojin Zhang; Xueying Chen; Li Wang; Haozhu Chen; Junbo Ge; Xian-Cheng Jiang
Journal:  Atherosclerosis       Date:  2019-04-14       Impact factor: 5.162

2.  Endothelial lipase increases antioxidative capacity of high-density lipoprotein.

Authors:  Irene Schilcher; Gerhard Ledinski; Snježana Radulović; Seth Hallström; Thomas Eichmann; Tobias Madl; Fangrong Zhang; Gerd Leitinger; Dagmar Kolb-Lenz; Barbara Darnhofer; Ruth Birner-Gruenberger; Christian Wadsack; Dagmar Kratky; Gunther Marsche; Saša Frank; Gerhard Cvirn
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2019-06-17       Impact factor: 4.698

Review 3.  Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases.

Authors:  Elena M G Diarte-Añazco; Karen Alejandra Méndez-Lara; Antonio Pérez; Núria Alonso; Francisco Blanco-Vaca; Josep Julve
Journal:  Int J Mol Sci       Date:  2019-12-12       Impact factor: 5.923

4.  Serum levels of small HDL particles are negatively correlated with death or lung transplantation in an observational study of idiopathic pulmonary fibrosis.

Authors:  Amisha V Barochia; Maryann Kaler; Nargues Weir; Elizabeth M Gordon; Debbie M Figueroa; Xianglan Yao; Merte Lemma WoldeHanna; Maureen Sampson; Alan T Remaley; Geraldine Grant; Scott D Barnett; Steven D Nathan; Stewart J Levine
Journal:  Eur Respir J       Date:  2021-12-02       Impact factor: 33.795

Review 5.  Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease.

Authors:  Diego Estrada-Luna; María Araceli Ortiz-Rodriguez; Lizett Medina-Briseño; Elizabeth Carreón-Torres; Jeannett Alejandra Izquierdo-Vega; Ashutosh Sharma; Juan Carlos Cancino-Díaz; Oscar Pérez-Méndez; Helen Belefant-Miller; Gabriel Betanzos-Cabrera
Journal:  Molecules       Date:  2018-10-23       Impact factor: 4.411

Review 6.  High Density Lipoproteins: Metabolism, Function, and Therapeutic Potential.

Authors:  Anne Jomard; Elena Osto
Journal:  Front Cardiovasc Med       Date:  2020-03-31

Review 7.  The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease.

Authors:  Jacek Rysz; Anna Gluba-Brzózka; Magdalena Rysz-Górzyńska; Beata Franczyk
Journal:  Int J Mol Sci       Date:  2020-01-17       Impact factor: 5.923

8.  Long-term fasting improves lipoprotein-associated atherogenic risk in humans.

Authors:  Franziska Grundler; Dietmar Plonné; Robin Mesnage; Diethard Müller; Cesare R Sirtori; Massimiliano Ruscica; Françoise Wilhelmi de Toledo
Journal:  Eur J Nutr       Date:  2021-05-07       Impact factor: 5.614

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.